Compare Amcor PLC (AMCR) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Novartis AG — how do they compare? Amcor PLC trades at $46.32 (market cap $21.92B), while Novartis AG trades at $152.64 (market cap $295.37B). The key difference: Novartis AG is far larger — about 13.5× Amcor PLC's market cap, and Amcor PLC pays the higher dividend (5.49%). Which is the better fit depends on your goals.
| AMCR | NVS | |
|---|---|---|
Market Cap | $21.92B | $295.37B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $168.62 |
52-Week Low | $36.69 | $119.31 |
Enterprise Value | $37.03B | $336.69B |
Dividend Yield | 5.49% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $47.11, down 1.57% today, near the consensus price target of $47.00. Recent quarters show consistent earnings beats, with Q4 2026 revenue up 26% year-over-year to $6.4 billion, driven by the Berry acquisition (PRNewsWire, Aug 12, 2026). Technical indicators signal a bullish trend, while valuation ratios like P/E of 38.07 appear elevated relative to historical margins. The company maintains a solid dividend, with a $0.65 payment scheduled for June 2026.
Outlook is cautiously optimistic given strong revenue growth and analyst buy ratings (64% consensus), but risks include high debt levels and margin pressure, with net income margin declining to 3.06% in 2025. Investors should weigh acquisition benefits against integration challenges and cyclical demand headwinds in packaging markets.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
